Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - Case report

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1611-1613

  Check, Jerome H ^a,b   Dix, Ebony ^a   Sansoucie, Lynn ^a   Check, Diane ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NONE   (United States)

Author keywords

Antagonist; Human colon cancer; Microenvironment; Natural killer cells; Progesterone receptor

Indexed keywords

MIFEPRISTONE; PROGESTERONE RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLON ADENOCARCINOMA; DRUG INHIBITION; HUMAN; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MIFEPRISTONE; NEOPLASM METASTASIS; QUALITY OF LIFE;

EID: 67650095289     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Szekeres-Bartho J, Kilar F, Falkay G, Csernus V, Torok A and Pacsa AS: Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol 9: 15-18, 1985.
2. Szekeres-Bartho J, Faust Zs, Varga P, Szereday L and Kelemen K: The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Am J Reprod Immunol 35: 348-351, 1996.
3. Check JH, Szekeres-Bartho J and O'Shaughnessy A: Progesterone induced blocking factor seen in pregnancy lymphocytes soon after implantation. Am J Reprod Immunol 35: 277-280,1996. (Pubitemid 26082218)
4. Check JH, Arwitz M, Gross J, Szekeres-Bartho J and Wu CH: Evidence that the expression of progesterone induced blocking factor by maternal T-lymphocytes is positively correlated with conception. Am J Reprod Immunol 38(1): 6-8, 1997. (Pubitemid 27308147)
5. Check JH, Ostrzenski A and Klimek R: Expression of an immunomodulatory protein known as progesterone induced blocking factor (PIBF) does not correlate with first trimester spontaneous abortions in progesterone supplemented women. Am J Reprod Immunol 37: 330-334, 1997.
6. Check JH, Nazari P, Goldberg J, Yuen W and Angotti D: A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypoth 57: 337-343, 2001. (Pubitemid 32822431)
7. Srivastava MD, Thomas A, Srivastava BIS and Check JH: Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymph 48(8): 1610-1617, 2007. (Pubitemid 47272811)
8. Chiu L, Nishimura M, Ishii Y, Wieda M, Maeshima M, Takedani Y, Shibata Y, Todokora K and Juji T: Enhancement of the expression of progesterone receptor on progesterone treated lymphocyte after immunotherapy in unexplained recurrent spontaneous abortion. Am J Reprod Immunol 35: 552-557, 1996. (Pubitemid 26172355)
9. Check JH, Sansoucie L, Chern J, Amadi N and Katz Y: The effect of treatment with a progesterone receptor antagonist on death from spontaneous lymphocytic leukemia in AKR/J mice. 97th Annual Meeting of the American Association for Cancer Research, Proceedings, Washington, DC, April 1-5, 2006, 47: 61, abstract #259.
10. Check JH, SanSoucie L, Chern J and Dix E: Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. 98th Annual Meeting of the American Association for Cancer Research Proceedings, Los Angeles, CA, April 14-18, 2007, abstract #1899.
11. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH and Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice by progesterone antagonist. Science 314: 1467-1470, 2006. (Pubitemid 44871955)